Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic pathways to glioblastomas.

Hiroko Ohgaki1

  • 1International Agency for Research on Cancer, Lyon, France. ohgaki@iarc.fr

Neuropathology : Official Journal of the Japanese Society of Neuropathology
|April 13, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Reply to Minhas and Tran.

International journal of radiation oncology, biology, physics·2019
Same author

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2018
Same author

Combination Therapy of Intravenously Injected Microglia and Radiation Therapy Prolongs Survival in a Rat Model of Spontaneous Malignant Glioma.

International journal of radiation oncology, biology, physics·2018
Same author

Germline MSH6 Mutation in a Patient With Two Independent Primary Glioblastomas.

Journal of neuropathology and experimental neurology·2017
Same author

CASP9 germline mutation in a family with multiple brain tumors.

Brain pathology (Zurich, Switzerland)·2016
Same author

Braf Mutations Initiate the Development of Rat Gliomas Induced by Postnatal Exposure to N-Ethyl-N-Nitrosourea.

The American journal of pathology·2016

Primary and secondary glioblastomas are distinct brain tumors with different genetic profiles. Understanding these differences, particularly in TP53 mutations and chromosome 10q alterations, is key to developing targeted therapies.

Area of Science:

  • Neuro-oncology
  • Cancer Genetics
  • Molecular Biology

Background:

  • Glioblastomas are aggressive brain tumors with two main subtypes: primary (de novo) and secondary (progression from lower-grade tumors).
  • These subtypes differ in patient age, genetic alterations, and developmental pathways.
  • Distinct genetic profiles suggest different origins and potential therapeutic targets.

Purpose of the Study:

  • To investigate and compare the genetic alterations in primary and secondary glioblastomas.
  • To identify specific genetic markers associated with each glioblastoma subtype.
  • To elucidate the distinct molecular mechanisms underlying glioblastoma development.

Main Methods:

  • Population-based study in Canton of Zürich, Switzerland.

Related Experiment Videos

  • Analysis of genetic alterations including loss of heterozygosity (LOH) on chromosome 10q, EGFR amplification, TP53 mutations, p16INK4a deletion, and PTEN mutations.
  • Detailed analysis of TP53 mutation hotspots and CpG site transitions.

    • Main Results:

    • Primary glioblastomas occur in older patients (mean 62 years) with frequent LOH 10q (69%) and other alterations (EGFR, TP53, p16INK4a, PTEN).
    • Secondary glioblastomas occur in younger patients (mean 45 years) with frequent TP53 mutations (65%) and LOH 10q (63%).
    • TP53 mutations in secondary glioblastomas show distinct patterns (hotspot codons, CpG site transitions) suggesting different mutagenic mechanisms, possibly involving alkylating agents and MGMT methylation.

    Conclusions:

    • Primary and secondary glioblastomas represent distinct molecular entities with different genetic underpinnings.
    • LOH on chromosome 10q is a common feature, potentially implicating a tumor suppressor gene in this region.
    • TP53 mutations arise through different mechanisms in each subtype, with implications for understanding glioblastoma pathogenesis and treatment.